SCHEMBL6613110

SCHEMBL6613110

CC(=O)NC[C@H]1CN(c2ccc(-c3cnc(N4CCN(C(=O)c5ccccc5C(F)(F)F)CC4)nc3)c(F)c2)C(=O)O1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAOA P21397 7/20 0.52
TOP2B Q02880 1/20 0.49
MAOB P27338 3/20 0.49
CALML3 P27482 2/20 0.49
LMNA P02545 1/20 0.49
PTGS1 P23219 1/20 0.49
SDHA P31040 1/20 0.49
SCD O00767 1/20 0.44
WDR5 P61964 1/20 0.43
CMA1 P23946 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797395 0.87 MAOA (0.53) MAOATOP2BMAOBCALML3LMNA
SCHEMBL6624452 0.87 MAOA (0.61) MAOAMAOBCALML3LMNAPTGS1
SCHEMBL6613114 0.87 CALML3 (0.44) MAOAMAOBCALML3SCDWDR5
SCHEMBL3195583 0.86 MAOA (0.60) MAOAMAOBCALML3LMNAPTGS1
SCHEMBL6645340 0.85 WDR5 (0.43) MAOAMAOBCALML3SCDWDR5
SCHEMBL6798382 0.85 MAOA (0.57) MAOATOP2BMAOBCALML3LMNA
SCHEMBL27592135 0.85 WDR5 (0.45) MAOACALML3SCDWDR5
SCHEMBL27592132 0.85 WDR5 (0.45) MAOACALML3SCDWDR5
SCHEMBL6797031 0.85 MAOA (0.57) MAOATOP2BMAOBCALML3LMNA
SCHEMBL6797699 0.85 MAOA (0.58) MAOAMAOBCALML3LMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689779-B2 PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY DONG A PHARM. CO., LTD. (KR) 2004-02-10 US claimed
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof DONG A PHARM. CO., LTD. (KR) 2003-09-04 US claimed
EP-1289984-A4 NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF DONG A PHARM CO LTD (KR) 2004-11-24 EP disclosed
US-6689779-B2 PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY DONG A PHARM. CO., LTD. (KR) 2004-02-10 US disclosed
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof DONG A PHARM. CO., LTD. (KR) 2003-09-04 US disclosed
EP-1289984-A1 NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF Dong A Pharmaceutical Co. Ltd. (KR) 2003-03-12 EP disclosed
WO-2001094342-A1 NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF DONG A PHARM. CO., LTD. (KR) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof OXA1L, ODC1, PDCD4 MAOA 763/4885TOP2B 820/4885MAOB 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.